QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: jpet.108.140327v1 327/2/411    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abramowski, D. Articles by Staufenbiel, M. Search for Related Content PubMed PubMed Citation Articles by Abramowski, D. Articles by Staufenbiel, M.

NEUROPHARMACOLOGY

Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following -Secretase Inhibition

Novartis Institutes for BioMedical Research, Basel, Switzerland

Human β-amyloid precursor protein (APP) transgenic mice are commonly used to test potential therapeutics for Alzheimer's disease. We have characterized the dynamics of β-amyloid (Aβ) generation and deposition following -secretase inhibition with compound LY-411575 [N²-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N¹-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. Kinetic studies in preplaque mice distinguished a detergent-soluble Aβ pool in brain with rapid turnover (half-lives for Aβ40 and Aβ42 were 0.7 and 1.7 h) and a much more stable, less soluble pool. Aβ in cerebrospinal fluid (CSF) reflected the changes in the soluble brain Aβ pool, whereas plasma Aβ turned over more rapidly. In brain, APP C-terminal fragments (CTF) accumulated differentially. The half-lives for -secretase degradation were estimated as 0.4 and 0.1 h for C99 and C83, respectively. Three different APP transgenic lines responded very similarly to -secretase inhibition regardless of the familial Alzheimer's disease mutations in APP. Amyloid deposition started with Aβ42, whereas Aβ38 and Aβ40 continued to turn over. Chronic -secretase inhibition lowered amyloid plaque formation to a different degree in different brain regions of the same mice. The extent was inversely related to the initial amyloid load in the region analyzed. No evidence for plaque removal below baseline was obtained. -Secretase inhibition led to a redistribution of intracellular Aβ and an elevation of CTFs in neuronal fibers. In CSF, Aβ showed a similar turnover as in preplaque animals demonstrating its suitability as marker of newly generated, soluble Aβ in plaque-bearing brain. This study supports the use of APP transgenic mice as translational models to characterize Aβ-lowering therapeutics.

Address correspondence to: Matthias Staufenbiel, Novartis Pharma AG, 4002 Basel, Switzerland. E-mail: matthias.staufenbiel{at}novartis.com

This article has been cited by other articles:

				P. Bach, J.-A. Tschape, F. Kopietz, G. Braun, J. K. Baade, K.-H. Wiederhold, M. Staufenbiel, M. Prinz, T. Deller, U. Kalinke, et al. Vaccination with A{beta}-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral A{beta} and Lowers Plaque Burden in APP Transgenic Mice J. Immunol., June 15, 2009; 182(12): 7613 - 7624. [Abstract] [Full Text] [PDF]